73 related articles for article (PubMed ID: 578759)
21. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
[TBL] [Abstract][Full Text] [Related]
23. Increased thromboxane metabolites excretion in liver cirrhosis.
Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
[TBL] [Abstract][Full Text] [Related]
24. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.
Karim A
Drug Metab Rev; 1978; 8(1):151-88. PubMed ID: 363379
[No Abstract] [Full Text] [Related]
25. Pharmacokinetics of spironolactone in man.
Abshagen U; Rennekamp H; Luszpinski G
Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
[TBL] [Abstract][Full Text] [Related]
26. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Sadée W; Schröder R; von Leitner E; Dagcioglu M
Eur J Clin Pharmacol; 1974; 7(3):195-200. PubMed ID: 4853286
[No Abstract] [Full Text] [Related]
27. New insights into the pharmacokinetics of spironolactone.
Overdiek HW; Hermens WA; Merkus FW
Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
[TBL] [Abstract][Full Text] [Related]
28. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
[TBL] [Abstract][Full Text] [Related]
29. [Elimination of 75Se-selenmethionine from the plasma of patients with liver disorders (author's transl)].
Pirwitz B
Przegl Lek; 1979; 36(7):573-6. PubMed ID: 504707
[No Abstract] [Full Text] [Related]
30. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Heazlewood V
Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
[TBL] [Abstract][Full Text] [Related]
31. [Biological availability of spironolactone in two different galenic forms (author's transl)].
Rameis H; Hitzenberger G; Horwatitsch H
Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone. I. Disposition and metabolism.
Karim A; Zagarella J; Hribar J; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing comparative bioavailability of spironolactone tablets.
Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey.
Hildebrand M; Krause W; Kühne G; Hoyer GA
Xenobiotica; 1987 May; 17(5):623-34. PubMed ID: 3604266
[TBL] [Abstract][Full Text] [Related]
35. [Biotransformation of prednisone to prednisolone in patients with liver cirrhosis].
Madsbad S; Bjerregaard B; Henriksen JH; Juhl E; Kehlet H
Ugeskr Laeger; 1979 May; 141(20):1325-8. PubMed ID: 452141
[No Abstract] [Full Text] [Related]
36. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.
Sungaila I; Bartle WR; Walker SE; DeAngelis C; Uetrecht J; Pappas C; Vidins E
Gastroenterology; 1992 May; 102(5):1680-5. PubMed ID: 1568578
[TBL] [Abstract][Full Text] [Related]
37. Electron microscopic studies on various types of inclusions found in autopsy cases. Part IV. Further observations on fine structures of spironolactone inclusion bodies.
Yamashita K; Nakano K; Okano K
Med J Osaka Univ; 1975 Mar; 25(3-4):141-52. PubMed ID: 177848
[No Abstract] [Full Text] [Related]
38. Spironolactone--a weak enzyme inducer in man.
Taylor SA; Rawlins MD; Smith SE
J Pharm Pharmacol; 1972 Jul; 24(7):578-9. PubMed ID: 4403853
[No Abstract] [Full Text] [Related]
39. Changes of fractional renal clearance of magnesium after spironolactone administration in normal subjects.
Mountokalakis T; Merikas G; Skipelitis P; Vardakis M; Sevastos N; Alivisatos J
Klin Wochenschr; 1975 Jul; 53(13):633-5. PubMed ID: 1177408
[TBL] [Abstract][Full Text] [Related]
40. Gas chromatographic determination of levels of aldadiene in human plasma and urine following therapeutic doses of spironolactone.
Chamberlain J
J Chromatogr; 1971 Mar; 55(2):249-53. PubMed ID: 5547796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
